Protara is committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease.
For more information, visit www.protaratx.com.
Company Details
- Employees
- 47
- Founded
- -
- Address
- 345 Park Avenue South,
- Phone
- 646-844-0337
- in****@****atx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- protaratx.com
- Keywords
- Rare Diseases, Parenteral Nutrition, Choline Deficiency, Metabolic Diseases, Orphan Diseases, Gastrointestinal Diseases, Short Bowel Syndrome, Drug Development, Corporate Development, Non-Muscle Invasive Bladder Cancer, Lymphatic Malformations.
- HQ
- New York, NY
Protara Therapeutics Questions
Protara Therapeutics's helpline number is 646-844-0337
Protara Therapeutics's website is protaratx.com
Protara Therapeutics's LinkedIn profile is https://www.linkedin.com/company/protara-therapeutics
Protara Therapeutics has
47 employees.
View email and phone details for 47
employees at Protara Therapeutics.
Protara Therapeutics's industry is
Biotechnology Research
Protara Therapeutics's top competitors are
Kingdom Supercultures,
Delcath Systems,
Anavex Life Sciences,
Aethon Therapeutics,
Nuvation Bio,
Biospherix, Llc,
Lexeo Therapeutics,
Immunic Therapeutics,
Envisagenics,
Transcend Therapeutics.
Protara Therapeutics's support email address is info@protaratx.com
Protara Therapeutics's categories are Biotechnology Research
Protara Therapeutics's founding year is 2017
